Top

Published in:

01-04-2012 | PRECLINICAL STUDIES

New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential

Authors: Maria Teresa Conconi, Giovanni Marzaro, Adriano Guiotto, Luca Urbani, Ilenia Zanusso, Francesca Tonus, Mara Tommasini, Pier Paolo Parnigotto, Adriana Chilin

Published in: Investigational New Drugs | Issue 2/2012

Summary

The antiangiogenic effects of three novel anilinoquinazoline derivatives were studied with the aim to find new multi-kinase inhibitors as anticancer agents. The compounds are characterized by dioxolane, dioxane and dioxepine rings and bear the same aniline substituent in 4 position as Vandetanib, known antiangiogenic agent. The in vitro assays were carried out on human umbilical vein endothelial cells (HUVECs), whereas in vivo angiogenesis was evaluated by means of Matrigel plug assay. The results showed that these compounds exert, even though to different extents, antiangiogenic activity affecting the various step of the process that leads to the formation of new blood vessels. At high concentrations they induced antiproliferative effects, whereas at non-cytotoxic concentrations they inhibited cell migration and the formation of tubular structures in Matrigel. In in vitro assays the dioxolane derivative 1 was more effective than Vandetanib. Indeed, it inhibited the effects induced by exogenous VEGF and FGF-2 on both cell proliferation and morphogenesis, whereas Vandetanib was completely ineffective. Moreover, all the compounds, as Vandetanib, counteracted the FGF-2-induced increase in the hemoglobin content in the Matrigel plugs. Our results showed that all the three novel derivatives possess both in vitro and in vivo antiangiogenic activity, with compound 1 more effective than Vandetanib to inhibit in vitro angiogenesis induced by exogenous cytokines.

Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr-Relat Cancer 12(Suppl 1):S17–S27PubMedCrossRef

Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev 7(7):505–516CrossRef

Takeuchi K, Ito F (2010) EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 277(2):316–326PubMedCrossRef

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRef

Przybylski M (2009) A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care 18(12):516–519PubMed

Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286PubMedCrossRef

Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5(3):203–220PubMedCrossRef

Ellis LM (2004) Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 18(5):1007–1021, viiiPubMedCrossRef

Birk DM, Barbato J, Mureebe L, Chaer RA (2008) Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovasc Surg 42(6):517–530CrossRef

10.

Ryan AJ, Wedge SR (2005) ZD6474–a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92(Suppl 1):S6–S13PubMedCrossRef

11.

Chilin A, Conconi MT, Marzaro G, Guiotto A, Urbani L, Tonus F, Parnigotto P (2010) Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold. J Med Chem 53(4):1862–1866PubMedCrossRef

12.

Marzaro G, Guiotto A, Pastorini G, Chilin A (2010) A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines. Tetrahedron 66(4):962–968CrossRef

13.

Fry DW (2003) Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res 284(1):131–139PubMedCrossRef

14.

Soares R, Guo S, Gartner F, Schmitt FC, Russo J (2003) 17 beta -estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis 6(4):271–281PubMedCrossRef

15.

Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF (2009) Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J Pharmacol Exp Ther 331(1):327–337PubMedCrossRef

16.

Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, Yan HJ, Tan L, Zeng YX, Huang W (2009) ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk Res 33(11):1512–1519PubMedCrossRef

17.

Munoz-Chapuli R, Quesada AR, Angel Medina M (2004) Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 61(17):2224–2243PubMedCrossRef

18.

van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I, Mous R, ten Klooster JP, Zwaginga JJ, Hordijk PL (2003) VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am J Physiol 285(2):C343–C352

19.

Gerety SS, Wang HU, Chen ZF, Anderson DJ (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4(3):403–414PubMedCrossRef

20.

Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, Goto H, Hanibuchi M, Nishioka Y, Ryan A, Sone S (2008) Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 265(1):55–66PubMedCrossRef

21.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M (2010) Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 127(5):1197–1208PubMedCrossRef

Title: New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential
Authors: Maria Teresa Conconi
Giovanni Marzaro
Adriano Guiotto
Luca Urbani
Ilenia Zanusso
Francesca Tonus
Mara Tommasini
Pier Paolo Parnigotto
Adriana Chilin
Publication date: 01-04-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9621-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2012

Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells

Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer